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This study examines the action of phorbol12-myristate 13-
acetate (PMA) on the synthesis of cholesterol sulfate in cul-
tured normal and transformed human epidermal keratino-
cytes and assesses the antagonistic effects by retinoids and 
bryostatins on PMA action in relation to the multistep pro-
gram of squamous differentiation. Treatment of normal 
human epidermal keratinocytes (NHEK) with PMA induces 
terminal cell division (irreversible growth-arrest) and causes 
a time- and dose-dependent increase in the incorporation of 
NalsS04 into cholesterol sulfate, a marker for squamous cell 
differentiation. This stimulation in sulfate incorporation ap-
pears specific for cholesterol sulfate and is due to increased 
levels of cholesterol sulfotransferase activity. The increase in 
cholesterol sulfate accumulation parallels the increase in 
transglutaminase type I, another marker for squamous differ-
entiation. Several transformed NHEK cell lines do not ex-
hibit increased levels of cholesterol sulfate and transgluta-
minase type I activity after PMA treatment, indicatin_s that 
they acquired defects in the regulation of squamous differen-
tiation. Bryostatins 1 and 2, and several diacylglycerol ana-
P horbol esters cause a variety of biologic and biochemical changes in the epidermis and in cultured epidermal kera-tinocytes and are potent tumor promoters for initiated mouse skin [1- 8]. Divergent responses to phorbol esters are observed in epidermal keratinocytes and appear to be 
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logues neither inhibit cell proliferation nor increase choles-
terol sulfate synthesis or trans glutaminase activity, indicating 
that these agents do not induce terminal differentiation. In 
contrast, the bryostatins block the increase in cholesterol sul-
fate and trans glutaminase activity as well as the commitment 
to terminal cell division by PMA. Bryostatin 1 inhibits the 
commitment to terminal cell division and the accumulation 
of cholesterol sulfate significantly even when added 8 h after 
PMA administration. Retinoids inhibit cholesterol sulfate 
accumulation and the increase in trans glutaminase activity by 
PMA but do not affect the commitment to terminal cell 
division. In summary, phorbol esters induce in NHEK cells a 
program of squamous differentiation. This process of differ-
entiation consists of the commitment to terminal cell divi-
sion and expression of the squamous phenotype. Expression 
of this rhenotype is accompanied by an accumulation of cho-
lestero sulfate and increased cholesterol sulfotransferase ac-
tivity. Bryostatins 1 and 2 and retinoic acid affect this differ-
entiation process at different stages.] Invest Dermatol93: 1 08-
115, 1989 
related to the presence of different subpopulations of basal cells. In 
one subpopulation phorbol esters elicit a proliferative response, 
whereas in another subpopulation they induce terminal differentia-
tion [9 - 16]. 
The major action of phorbol esters in eukaryotic cells is mediated 
by the activation of protein kinase C [17,18], which is encoded by a 
family of closely related genes [19,20]. Protein kinase C plays a role 
in signal transduction for a wide variety of hormones that cause 
increased phospholipase C activity resulting in the formation of 
diacylglycerol, the endogenous activator of protein kinase C [18]. 
Although several differences between the action of diacylglycerols 
and phorbol esters have been demonstrated, treatment of cells with a 
diacyl!$lycerol elicits many of the same responses as with phorbol 
esters [21 - 26]. 
Bryostatins are macrocyclic lactones isolated from the marine 
bryozoan Bugula neritina [27]. Their chemical structure is different 
from that of phorbol esters although they contain functional groups 
homologous to the postulated phorbol ester pharmacophore. 
Bryostatins compete effectively for phorbol ester binding, activate 
protein kinase C, and induce a redistribution of protein kinase C 
[2B - 31]. Bryostatills mimic several of the effects of phorbol esters 
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in pro myelocytic leukemia HL60 cells [29,30], mouse epidermal 
keratinocytes [32], and in GH rat pituitary cells [26]. Bryostatin 1, 
however, not only failed to induce differentiation in HL60 cells 
[29], mouse epidermal keratinocytes [32], and in a human colon 
cancer cell line YOM [33], but blocked the induction of differentia-
tion when administered in conjunction with phorbol esters. 
Treatment of normal human epidermal keratinocytes (NHEK) in 
culture with phorbol esters induces in most cells a pathway of squa-
mous cell differentiation [12,13]. We have recently shown that 
cholesterol sulfate synthesis increases dramatically during epider-
mal differentiation in vitro and functions as a biochemical marker 
for the process of squamous differentiation [34-36]. In the skin, 
increased accumulation of cholesterol sulfate has been demonstrated 
in the granular and cornified layers [37,38]. In this study, we exam-
ined the action of the phorbol ester phorbol 12-myristate-13-ace-
tate (PMA) and several diacylglycerol and bryostatin analogues on 
the synthesis of cholesterol su lfate in relation to the multistep pro-
cess of differentiation in NHEK cells [34] . In addition, the effect of 
retinoic acid, a known inhibitor of PMA action [39], on PMA-in-
duced accumulation of cholesterol sulfate was determined. 
MATERIALS AND METHODS 
Cell Culture Second passage cultures of normal epidermal kerati-
nocytes from human foreskin were obtained from Clonetics, 
Boulder, CO. The NHEK cells were grown in modified MCDB 
153 medium containing 0.13 mM CaCI2 and supplemented with 
10 ng/ml epidermal growth factor (EGF), 5 }lg/ml insulin, 1.4 }lM 
hydrocortisone, 0.1 mM ethanolamine and )?hosphoethanolamine, 
and bovine pituitary extract (BPE; 50 }lg/ml) as described by Boyce 
and Ham [40]. This medium is referred to as KGM and was obtained 
from Clonetics. Experiments were carried out with cells from the 
third passage. The human epidermal squamous cell carcinoma cell 
lines SCC13 [41] and SQCC/Yl were obtained from Dr. J. G. 
Rheinwald (Harvard Universiry, Boston, MA) and Dr. J. A. 
McLane (Hoffman-La Roche, Nutley, NJ). The NHEK-SV40-T8 
and the NHEK-TIl are cell lines obtained after infection of NHEK 
cells with a retroviral shuttle vector containing the gene for SV40-
large T antigen [34]. The NHEK-SV40-T8-1 is an immortal cell 
line obtained from NHEK-SV 40-T8 cells after they underwent 
"crisis" [34,42]. All cell lines were grown in KGM medium in a 
humidified atmosphere of 5% CO2 and 95% air at 37°C. Colony-
forming efficiency, defined as the percentage of plated cells able to 
form a colony, was determined as described previously [34]. The 
1,2-diacylglycerol analogues (Sigma, St. Louis, MO and Serdary 
Research Laboratories, London, ON) were dissolved in ethanol. 
The PMA (LC Services Corp., Woburn, MA) and bryostatins 1 and 
2 were dissolved in dimethylsulfoxide. Bryostatins were isolated 
and purified from BugtiIa IJeritina as described previously [27]. The 
NHEK cells growing in the early exponential phase were treated 
with 20 nM PMA for 48 h, unless indicated otherwise. 
Assay of Cholesterol Sulfate Cells were metabolically labeled 
by incubating for 24 h with Na235S0~ (10 - 50 }lCi/ml; carrier-free; 
ICN, Irvine, CA) and [5-3HJ-mevalonolactone (50 .uCi/ml; 30 Ci/ 
1nmol; Dupont, Boston, MA). Cells were harvested by trypsiniza-
tion, pelleted, and extracted with 4 ml chloroform/methanol (CM) 
(2: 1) as described previously [36]. The insoluble residue (desig-
nated as the CM-insoluble fraction) was pelleted by centrifugation 
and dissolved in 10% sodium dodecyl sulfate. Aliquots were taken 
to determine radioactivity and protein content [36]. The remaining, 
CM-soluble fraction was extracted sequentially with 1 ml 0.1 M 
KCI and 2 ml methanol/O.l M KCI (1: 1). The resulting organic 
phase was isolated, taken to dryness and radioactivity determined. 
The variation in the cholesterol sulfate determination between du-
plicates was 15% or less. The radiolabeled material was analyzed 
further by thin-layer chromatography using silica gel G plates (An-
altech , Newark, DE) and CHCI3/CH30H/acetone/glacial acetic 
acid/H20 (8: 2 : 4: 2 : 1) as solvent system. The labeled material 
migrated as a single peak that co-migrated with cholesterol sulfate. 
Sulfated glycolipids were not detected. 
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Transglutaminase Assays Cells grown in 60-mm dishes were 
washed in cold phosphate-buffered saline containing 1 roM EDT A 
and 1 mM phenylmethyl-sulfonyl fluoride. Cells were disrupted by 
three freeze and thaw cycles [42]. The homogenate was centrifuged 
at 105,000 g, yielding the particulate and soluble fractions. Trans-
glutaminase assays were performed on the total homogenate and on 
the particulate (rype I transglutaminase) and soluble (rype II trans-
glutaminase) fra<:tions. Transglutaminase activity was measured by 
determining the incorporation of [3H] putrescine (16.2 Ci/mmol, 
Dupont, Boston, MA) into casein hydrolysate as described pre-
viously [43]. 
Assay for Cholesterol Sulfotransferase Activity Sulfotrans-
ferase activiry was determined as described [44]. Briefly, cells were 
harvested by trypsinization, pelleted by centrifugation, and the re-
sulting pellet was resuspended in 50 mM HEPES, pH 7.3. Suspen-
sions were 3 times alternately frozen in a dry ice - methanol bath and 
thawed in a 40°C water bath. After centrifugation (13,000 g, 
t 5 min, 4 ° C), the supernatant was assayed for sulfotransferase ac-
tivity. Assay mixtures (total volume 100 }ll) contained 50 mM 
HE PES (pH 7.3), 0.01% Triton X-I00, 200 roM NaCI, 2.6 mM 
cholesterol, 1.8.uM 3sS-labeled 3'-phosphoadenosine-5'-phospho-
sulfate (106 dpm; Dupont), and the crude enzyme preparation 
(100-400}lg protein). Incubations were performed at 37°C for 
60 min and the reactions were terminated by the addition of 4 ml 
CM (2: 1), followed by the addition of 1 ml of 0.1 M KC!. After 
vortexing and centrifugation, the radioactivity in the organic phase 
was determined. 
Epidermal Growth Factor-Binding Assay The NHEK cells 
were grown in KGM medium in 60-mm dishes. When the cultures 
reached a density of 4 X 105 cells/dish, cells were washed in KGM 
medium without EGF and BPE and incubated for an additional 15 h 
in the same medium. Cultures were then treated with PMA, a dia-
cylglycerol, or a bryostatin. After 20 min incubation cells were 
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Figure 1. Time course for the stimulation of cholesterol sulfate accumula-
tion and transglutaminase activity in NHEK cells by PMA. Cells in the 
exponential growth phase were treated with PMA in solvent (20 nM; closed 
symbols) or with solvent only (dimethylsulfoxide, 0.1 % final concentration; 
OpelJ symbols). At the indicated times the cholesterol sulfate accumulation 
(triangles) or transglutaminase activity (circles) was determined. [35SJsuifate 
incorporation into cholesterol sulfate was measured over a period of 6 rather 
than 24 h. 
Figure 2. Dose-response curve for the induction of cholesterol sulfate syn-
thesis and trans glutaminase type I activity by PMA in NHEK cells. Cells 
were treated in the exponential phase with PMA at the indicated concentra-
tion in the presence of the regular (0.13 mM) Ca++- concentration (Opell 
symbols) or 1.6 mM Ca++- (closed symbols) . A: Cholesterol sulfate accumula-
tion; B: transglutaminase type I activity. 
washed with medium and incubated with 2 ml medium containing 
1 mg/ml bovine serum albumin and 125I_EGF (1 ng/ml, 176 p,Ci/ 
p,g, Dupont) for 3 h at O°C. Cells were washed, solubilized, and 
radioactivity counted as described previously [23]. 
RESULTS 
Cholesterol Sulfate Accumulation Recently, we reported that 
in several cell types the expression of the squamous cell phenotype is 
accomranied by an increased accumulation of cholesterol sulfate 
[34,36 . In this study we examined the effect ofPMA on cholesterol 
sulfate synthesis in cultured NHEK cells. During the exponential 
phase, NHEK cells exhibited low levels of cholesterol sulfate. 
Treatment of these cells with PMA increased greatly the levels of 
cholesterol sulfate. 
The time course of the increase in cholesterol sulfate accumula-
tion is shown in Figure 1. After a lag period of about 6 to B h, 
PMA-treated NHEK cells showed a rapid increase in cholesterol 
sulfate levels. A maximum accumulation of cholesterol sulfate was 
reached after 24 h ofPMA treatment. This level was about 20-fold 
higher than that in control cells. The increase in cholesterol sulfate 
production followed the same kinetics as the induction of transglu-
taminase type I activity, another marker of squamous differentiation 
that has been shown to increase after PMA treatment of mouse 
epidermal keratinocytes [39,45]. Untreated NHEK cells main-
tained relatively low levels of cholesterol sulfate and transglutami-
nase activity during the exponential phase but increases in both 
markers occur when cells reach the stationary phase of growth at 
about 5 to 6 d after plating [34] . 
The stimulation of cholesterol sulfate accumulation was depen-
dent on the concentration ofPMA (Fig 2). Half-maximum stimula-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
tion occurred at 0.3 nM PMA similar to that for the half-maximum 
induction of transglutaminase activity. High calcium concentra-
tions in the medium (1.6 mM instead of 0.13 mM) enhanced the 
stimulation of cholesterol sulfate accumulation by PMA about two-
fold; however, this stimulation was not always seen and appeared to 
depend largely on the epidermal keratinocyte donor (compare Fig 2 
and Table I). High calcium consistently did not enhance particulate 
(type I) transglutaminase activity. 
Cholesterol Sulfotransferase The increase in the incorporation 
of radiolabeled sulfate into cholesterol sulfate was specific as no 
increase of the incorporation into the chloroform/methanol insolu-
ble material was observed (Table I). To determine whether the 
increase in the synthesis of cholesterol sulfate was related to an 
increase in the enzyme cholesterol sulfotransferase, the level of this 
enzyme activity in PMA treated and untreated cells was determined 
(Table I). A good correlation was found between the levels of cho-
lesterol sulfate and sulfotransferase activity, suggesting that the in-
crease in cholesterol sulfate was largely due to increased sulfotrans-
ferase activity. 
Transformed Cells The effect of PMA was examined further in 
several transformed cell lines (Table II). The response of NHEK-
SV 40-TB and NHEK-T11 cells to PMA was very similar to that of 
NHEK cells: after PMA treatment, these cells showed a substantial 
increase in both cholesterol sulfate accumulation and transglutarni-
nase type I activity. In contrast, NHEK-SV40-TB-l, an immortal 
cell line obtained after NHEK-SV40-TB underwent "crisis" 
[34,41], and the epidermal squamous carcinoma cell lines SCCl3 
and SCC/Yl were much more resistant to PMA. In contrast to 
NHEK cells, which became growth-arrested after PMA treatment, 
growth of SCC13 cells was only slightly inhibited (Fig·3). Similar 
observations as for SCC13 cells were made for NHEK-SV40-TB-1 
and SeC/Yl cells (not shown). In these transformed cell lines PMA 
induced only a slight increase in the two differentiation parameters 
(Table II) . 
Bryostatins and Diacylglycerols The action of several bryosta-
tin and diacylglycerol analogues, each of which can bind to and 
activate protein kinase C, on NHEK cells was examined and com-
pared with the effects induced by PMA. Like PMA, these agents 
were able to reduce the binding ofEGF in NHEK cells (Fig 4) as has 
been reported previously in other cell systems [24,32]. The binding 
of EGF to SCCl3 cells showed the same sensitivity to PMA and 
bryostatin 1 as that to NHEK cells. The concentrations of half-
maximum inhibition were approximately 0.3 nM, 0.3 nM, and 
2 p,M for PMA, bryostatin 1, and dioctanoylglycerol, respectively. 
In contrast to the action of PMA, however, bryostatins and diacyl-
glycerols neither induced a reduction in colony-forming efficiency 
(Table III) nor caused a cessation of cell proliferation (Fig 3) and 
they did not induce the change in cellular morphology characteris-
tic for PMA-treated cells. In addition, treatment of NHEK cells 
with a bryostatin or diacylglycerol did not increase cholesterol sul-
fate accumulation or transglutaminase type I activity (Table III). 
Similar results as for bryostatin 1 and dioctanoylglycerol were ob-
ta.ined when bryostatin 2 or didecanoylglycerol or oleyl-acetyl-
Table I. Effect of PMA on Accumulation of Cholesterol Sulfate in Comparison with Cholesterol Sulfotransferase Activity 
CM Insoluble Pellet 35S-Cholesterol Sulfate Sulfotransferase Activity 
Condition' (dpm/J.Lg protein) (dpm/J.Lg protein) (dpm/h/J.Lg protein) 
0.13 mM Ca++- NA 3210 ± 63 23± 4 (1) 770 (1) 
PMA 2740 ± 260 300 ± 26 (13) 6470 (8.4) 
1.6 mM Ca++ NA 1990 ± 248 21 ± 0.7 (0.9) 990 (1.3) 
PMA 2300 ± 238 288±43 (12) 8890 (11.5) 
• The NHEK cells were treated in the exponential growth phase (2 X lOS cells/60-mm dish) with PMA (20 nM). After 24 h cells were incubated further in the presence of 0.13 
rnM or 1.6 rnM Ca++ and labeled with Na/sSO, (50 pCi/ml) for an additional 24 h. Cells were collected and incorporation into CM-insoluble material (CM insoluble pellet) .nd 
into cholesterol sulfate determined. Sulfotransferase activity was determined using separate dishes as described in Materials .tld Methads. NA indicates cells that were treated with 
solvent OM SO (0.1 %) only. Numbers between parentheses indicate fold-increase over control (NA) value. 
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Table n. Effect of PMA on Accumulation of Cholesterol Sulfate and Transglutaminase Type I Activity in Normal and 
Transformed Epidermal Keratinocytes 
[3SSJCholesterol Sulfate Particulate Transglutaminase Activity 
Cells' Treatment (dpm/JJg protein) (cpm/h/JJg protein) 
NHEK NA 0.3 1.1 ± 0.2 
PMA 31.S (106)1 31.5 ± 2.0 
NHEK-SV40-TS NA 0.6 1.4 ± 0.2 
PMA 27.6 (46) S.O ± 0.6 
NHEK-SV40-Tl1 NA 0.4 O.S ± 0.2 
PMA 29.0 (73) 6.5 ± 0.5 
NHEK-SV40-TS-l NA 1.0 1.1 ± 0.2 
PMA 2.0 (2) 2.7 ± 0.7 
SCC13 NA 2.9 O.S ± 0.2 
PMA 10.7 (3.7) 0.6 ± 0.2 
SCC/Yl NA 0.6 0.2 ± 0.1 
PMA 0.9 (1.5) 0.3 ± 0.1 
• Cells were treated in the exponential growth phase (approximately 2 X 10' cells/60-mm dish) with 30 nM PMA for 48 h and then assayed for cholesterol sulfate production and 
particulate trallSglutaminase activity. Cells were labeled with Nal'SO. 24 h before harvesting. Controls received the solvent dimethylsulfoxide. Variation between duplicate values 
of cholesterol sulfate was 15% or less. NA indicates cells that were treated with solvent DMSO only (0.1%). 
• Numbers between paxentheses indicate fold-increase over control value (NA). 
glycerol were used (Table III) . These results indicate that these 
agents can mimic some but not all of the responses to PMA in 
NHEK cells. 
Recently it has been shown in several cell systems that bryostatins 
can antagonize certain effects of PMA [29 -33]. We conducted 
experiments to assess whether a bryostatin would prevent PMA-in-
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Figure 3. Action of PMA and bryostatin 1 on the growth of NHEK and 
SCC13 cells. Cells were treated in the exponential phase (S X 10' cells/60-
mm dish) with PMA or bryostatin 1 at the concentrations indicated. After 4 d 
total cell number was determined. 0, NHEK cells treated with PMA; . , 
NHEK cells treated with bryostatin 1; 1:::., SCCD cells treated with PMA. 
duced differentiation in NHEK cells. When NHEK cells were 
treated simultaneously with bryostatin 1 and PMA, bryostatin in-
hibited the change in cellular morphology, the accumulation of 
cholesterol sulfate, and the increase in transglutaminase type I activ-
ity in a dose-dependent manner (Fig 5). Bryostatin 1 caused half-
maximum inhibition (EC50) of cholesterol sulfate accumulation at 
approximately 1 nM, similar to that for the inhibition of transglu-
taminase type I activity. Bryostarin 2 exhibited a similar action as 
bryostatin 1. inhibiting the expression of the two differentiation 
markers. cholesterol sulfate and trans glutaminase type I (Table Ill). 
Bryostatins also antagonized the growth-inhibitory effects of 
PMA in NHEK cells. The NHEK cells treated with PMA became 
growth-arrested and underwent terminal cell division as indicated 
by a reduction in colony-forming efficiency (Table III; Refs 12,13). 
Bryostatin 1 blocked the inhibition of proliferation in NHEK cells 
by PMA (Fig 6). The EC50 for this action ofbryostatin 1 was 1 nM, 
similar to that for the inhibition of the expression of the differentia-
tion markers. Bryostatin 1 and 2 also inhibited the reduction in 
colony-forming efficiency in NHEK cells after PMA treatment 
(Table III). suggesting that bryostatins prevent the cells from un-
dergoing terminal cell division. 
The bryostatins not only antagonized the action of PMA when 
added simultaneously to NHEK cells, but was also active when 
added after the administration of PMA. Figure 7 shows that after 
8 h of PMA treatment, the addition of bryostatin 1 still caused a 
50% reduction in cholesterol sulfate accumulation and in transglu-
taminase activity. Similar observations were made when colony-
forming efficiency was measured (not shown). 
Inhibition by Retinoids When NHEK cells were treated simul-
taneously with retinoic acid and PMA. cells still underwent termi-
nal cell division as indicated by the reduction in colony-forming 
efficiency and cells exhibited a morphology typical for PMA-
treated cells (Table III). Retinoic acid, however, inhibited the in-
crease in cholesterol sulfate accumulation as well as the increase in 
transglutaminase type I activity. 
DISCUSSION 
In this study the effect of PMA on the synthesis of cholesterol 
sulfate in NHEK cells was examined in relation to the process of 
terminal differentiation. Treatment of NHEK cells with PMA in-
duces an increase in the accumulation of cholesterol sulfate with 
kinetics tha.t parallel the increase in transglutaminase type 1 activity, 
a well-described marker of squamous differentiation [39,43,46]. 
This increase in cholesterol sulfate is largely due to an increase in 
cholesterol sulfotransferase activity, the enzyme catalyzing the for-
mation of cholesterol sulfate. These findings further support our 
previous conclusion that cholesterol sulfate accumulation is a sensi-
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Figure 4. Effect of PMA, dioctanoylglycerol, and bryostatin 1 on EGF 
binding in NHEK and SCC13 cells. Cells were treated for 20 min with 
PMA, dioctanoylglycerol, or bryostatin 1 at the concentrations indicated. 
The EGF binding was determined at O°C as described in Materials and 
Methods. 0, NHEK cells; e, SCC13 cells. 
tive biochemical marker for squamous cell differentiation in several 
cell types [34,43,44). The increase in cholesterol sulfate, which we 
have observed in cultured NHEK cells undergoing squamous dif-
ferentiation, is physiologically relevant, as in normal skin choles-
terol sulfate synthesis increases in the spinous and granular layers; 
the highest levels of cholesterol sulfate occurring in the granular 
and cornified layers [37,47]. These layers exhibit a cholesterol to 
cholesterol sulfate ratio of 5: 1 to 10: 1, whereas in most epithelial 
tissues this ratio is approximately 500: 1. The function of choles-
terol sulfate is unknown. Cholesterol sulfate has been shown to 
inhibit sterologenesis in cultured fibroblasts and NHEK cells by 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and 
to affect fatty acid metabolism [48,49], suggesting a possible role for 
cholesterol sulfate as a modulator of lipid metabolism. Alterna-
tively, cholesterol sulfate may alter the activity of specific mem-
brane proteins via changes in the conformation or fluidity of the 
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Figure S. Antagonism between PMA and bryostatin 1 on the synthesis of 
cholesterol sulfate and transglutaminase type I activity. The NHEK cells 
were treated simultaneously with PMA (20 nM) and bryostatin 1 at the 
concentrations indicated. After 40 h incubation, cells were harvested and the 
accumulation of cholesterol sulfate (A) and transglutaminase type I activity 
(B) determined. Cells were labeled with NalsSO. 24 h before harvesting 
the cells. 
membrane or function as a receptor for protein precursors of the 
cross-linked envelope. 
The cell lines NHEK-SV40-T8-1, SCC13, and SCC/Y1 are not 
irreversibly growth-arrested and do not express increased levels of 
cholesterol sulfate and transglutaminase type I activity after PMA 
treatment. These observations are in agreement with the concept 
that these virally transformed and carcinoma cells are resistant to 
PMA-induced differentiation and have acquired defects in their 
control of proliferation and differentiation as has been proposed 
previously [2,13,34,41,50-52]. Conceivably, certain carcinoma 
cells may have acquired a defect in the synthesis, activation, or 
function of a specific protein kinase C isozyme. Alternatively, the 
resistance to PMA-induced differentiation may be related to 
the activation of a specific oncogene in a manner analogous to the 
v-Ha-ras-induced resistance to PMA in mouse epidermal keratino-
cytes [50]. 
Phorbol esters elicit a diverse set of responses in epidermal kerati-
nocytes [1 - 7]. Evidence has been accumulated that indicates that in 
Table m. Action of Bryostatins, Retinoids, and Diacylglycerol Analogues on Accumulation of Cholesterol Sulfate and 
Transglutaminase Activity in NHEK Cells 
[JSS)Cholesterol Sulfate Transglutaminase Activity CFE 
Treatment" (dpm/Jlg protein) (cpm/h/Jlg protein) % 
NA 19.0 (1)~ 0.4 ± 0.1 48 ± 5 
PMA (20 nM) 325.8 (17) 5.2 ± 0.5 <0.1 
Bryostatin 1 (100 nM) 21.0 (1.1) 0.3 ± 0.1 41 ± 4 
Bryostatin 2 (100 nM) 20.4 (1.1) 0.3 ± 0.1 39± 5 
Retinoic acid (500 nM) 9.6 (0.5) 0.4 ± 0.2 35 ±4 
Ch55 (50 nM) 11.2 (0.6) NT 36± 4 
PMA + bryostatin 1 25.7 (1.4) 0.3 ± 0.2 32± 6 
PMA + bryostatin 2 14.2 (0.7) 0.4 ± 0.1 37± 3 
PMA + retinoic acid 93.9 (4.9) 1.1 ± 0.3 <0.1 
PMA + Ch55 102.8 (5.4) NT <0.1 
Dioctanoylglycerol (150 JlM) 12.7 (0.7) 0.3 ± 0.1 43 ±4 
Didecanoylglycerol (150 liM) 33.5 (1.8) 0.3 ± 0.1 41 ± 6 
Oleyl-acetyl glycerol (150 JlM) 19.2 (1.0) 0.7 ± 0.2 NT 
• Logarithmic cultures ofNHEK cells were treated with the indicated compounds for 48 h and then .ssayed for colony-forming eRiciency (CFE), cholesterol sulfate .ccumul.tion, 
.nd particulace tronsglutaminase .ctivity. For measurement of cholesterol production, cells were labeled 24 h before harvesting. NA indicates cells that were tre.ted with solvent 
DMSO only. Ch 55 - benzoic .cid analog of retinoic .cid. 
I Numbers between parentheses indicate fold-increase over control value (NA). NT - not tested. 
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Figure 6. Antagonism between PMA and bryostatin 1 on the cell prolifera-
tion of NHEK cells. NHEK cells (at a cell density of2.0 X 105 cells/60-mm 
dish) were treated simultaneously with PMA (20 nM) and bryostatin 1 at the 
concentrations indicated. After 24 h, medium was renewed and cells incu-
bated further in the absence ofPMA or bryostatin. After 3 d cell number was 
determined . • , control NHEK cells; 0, PMA-treated cells. 
epidermal cells in culture, as well as in vivo, the different responses 
are related to different subpopulations of undifferentiated cells 
(basal cells) (13 -16). In one subpopulation (subpopulation A; Fig 8) 
phorbol esters induce a proliferative response as indicated by the 
increase in 3H-thymidine incorporation and stimulation of orni-
thine decarboxylase activity. In the other subpopulation (subpopu-
lation B; Fig 8) phorbol ester treatment causes terminal differentia-
tion. This pathway of differentiation appears to occur in several 
stages [34,52,53]; in the initial stage cells undergo terminal cell 
division (irreversible growth-arrest) as indicated by the decrease in 
colony-forming efficiency. In subsequent stages, cells start to ex-
press a squamous phenotype as indicated by the increase in choles-
terol sulfate synthesis [34], increased sulfotransferase and transglu-
taminase type I activity [34,39,46] and finally the formation of 
cross-linked envelopes [54] . It appears that the commitment to ter-
minal cell division is required before differentiation markers are 
expressed in NHEK cells [52,53) . The conversion of "subpopula-
tion A" cells to "subpopulation B" cells may be a reversible process. 
It is not known what molecular differences underlie the different 
responsiveness to phorbol esters in the two subpopulations. Cul-
tures of NHEK cells maintained in KGM medium appear to consist 
of mostly "subpopulation B" cells as addition of phorbol esters cause 
terminal cell division and expression of the differentiated pheno-
type in most cells [12,13] . Under these conditions, however, NHEK 
cells do not undergo complete differentiation as other differentia-
tion markers, such as high molecular weight keratins or filaggrin, 
are not expressed [53). Expression of these differentiation character-
istics may constitute a later step in the differentiation process. 
Bryostatins bind to and activate protein kinase C [28 - 31]' Like 
phorbol esters, they induce ornithine decarboxylase and 3H-thymi-
dine incorporation in "subpopulation A" mouse epidermal cells 
[32]. Bryostatins, however, do not induce terminal differentiation 
in "subpopulation B" mouse epidermal cells [32] or in NHEK cells, 
as phorbol esters do. In contrast, bryostatins inhibit terminal differ-
entiation induced by PMA (Figs 3 and 5; Ref32). Bryostatin inhibits 
both the commitment to terminal cell division as well as the eXfres-
sion of the differentiated phenotype. The molecular basis 0 this 
antagonism is not yet understood. Epidermal keratinocytes may 
express several protein kinase C isoenzymes that could be affected 
by phorbol esters and bryostatins in different ways in terms of affin-
ity, down-regulation, or substrate specificity [26 - 32]. Studies in 
Friend leukemia cells showed that bryostatins inhibit phorbol ester 
action in a noncompetitive manner [55]. In human promyelocytic 
leukemia HL60 cells bryostatins induce the phosphorylation of a 
unique set of proteins [56]. These findings support the hypothesis 
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that bryostatins interact with either a protein kinase C isozyme with 
low affinity for phorbol esters or with a protein distinct from pro-
tein kinase C. Recent studies by Fields et al [57] indicated that 
bryostatin 1, but not phorbol esters, activates (a) protein kinase Cat 
the nuclear membrane and induces rapid phosphotylation of nuclear 
envelope proteins. These observations are in agreement with the 
concept that bryostatin can selectively activate protein kinase C, 
possibly a specific protein kinase C isozyme. It is conceivable that 
the antagonism between bryostatins and PMA in NHEK cells is 
related to a similar mechanism. The selective activation of one pro-
tein kinase C isozyme generates a signal that antagonizes the signal 
generated by the activation of another protein kinase C isozyme. 
Bryostatin 1 can block terminal differentiation in NHEK cells 
long after the administration of PMA. A similar observation has 
been made for the antagonistic action of bryostatin 1 on PMA-in-
duced differentiation in HL60 cells [29] . This finding indicates that 
the PMA-induced commitment to terminal cell division in NHEK 
cells does not occur rapidly but is a relatively late event. The cause 
for this delay in commitment is not known. Possibly, the commit-
ment to terminal differentiation can only take place in a specific 
phase of the cell cycle as has been proposed previously [58]. 
Diacylglycerol analogues, although activating protein kinase C 
and eliciting the early changes induced by protein kinase C, such as 
reduction in EGF-binding (Fig 4; Refs 24,32), are not very effective 
inducers of the late effects such as growth-arrest and increase in 
cholesterol sulfate accumulation (Table III; Ref 32). The latter ob-
servation is in agreement with the poor induction of transglutamin-
ase activity by diacylglycerols re£orted in mouse epidermal cells 
[25]. In other cell systems as welll22,23,26], diacylglycerols do not 
mimic all the effects ofPMA; this may be at least partially due to the 
poor uptake and rapid metabolization of diacylglycerols or due to 
activation of specific protein kinase C isozymes. 
Retinoic acid has a quite different effect from bryostatins on the 
process of terminal differentiation induced by phorbol esters. Reti-
noic acid treatment does not prevent the reduction in colony-form-
ing efficiency induced by PMA, but does inhibit the accumulation 
of cholesterol sulfate and the increase in transglutaminase type 1 
activity in NHEK cells [39,59]. These results suggest that retinoic 
acid does not affect the commitment to terminal cell division but 
does inhibit the expression of the differentiated phenotype (Fig 8). 
Studies in mouse epidermal keratinocytes have shown that retinoic 
acid can also inhibit the induction of ornithine decarboxylase activ-
ity by PMA in "population A" cells [60], indicating that rerinoie 
acid can act at more than one stage in the differentiation process. 
The mechanism by which retinoic acid inhibits the expression of 
TIME OF BRYOSTATIN AOOITION 
( hr.) 
Figure 7. Time-dependent inhibition of the action ofPMA by bryostatin 1. 
The NHEK cells were treated with PMA (20 nM) and at different rime 
intervals after the addition ofPMA, bryostatin 1 (100 nM) was added. After 
24 h medium was renewed and cells incubated for an additional 24 h in the 
presence of bryostatin only. At that time cholesterol sulfate accumulation 
(0) and transglutaminase (type I) activity (~) were determined. Cells were 
labeled with Na23SSO. 24 h before harvesting. 
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Figure 8. Schematic view of the mechanisms by which the phorbol ester PMA. bryostatins. and retinoic acid modulate squamous cell differentiation in 
tracheobronchial and epidermal epithelial cells. In cell subpopulation A. PMA induces cell proliferation as indicated by increased ornithine decarboxylase 
activity (ODC) and lH-thymidine incorporation. Subpopulation A cells can convert reversibly into subpopulation B cells. which respond to PMA in 
subpopulation A cell. In subpopulation B cells. however. bryostatins antagonize the induction of squamous cell differentiation by PMA. The bryostatins block 
both the induction of terminal cell division (irreversible growth-arrest) as well as the expression of the differentiated phenotype. In contrast, retinoic acid does 
not influence the commitment to terminal cell division but does inhibit the expression of the differentiated phenotype. This model is based on a culmination of 
findings reported in this study and in Refs 2. 3. 9-16. 32.34. and 45. 
the squamous differentiated phenotype is not known. Previous 
studies [34] have indicated that retinoids act at low concentrations 
(nmolar range) and with a certain structural specificity. suggesting 
that specific high affinity receptors are involved in mediating the 
action of these agents. Recent studies Oetten AM. unpublished ob-
servations} have shown that NHEK cells contain nuclear retinoic 
acid receptors. These nuclear receptors have been shown to be tran-
scriptional factors and members of the steroid/thyroid hormone 
receptor family [61.62]. The binding of retinoids to this nuclear 
retinoic acid receptor exhibits a similar structure-activity relation-
ship as that of the inhibition of squamous differentiation Oetten 
AM. unpublished observations). These findings support the concept 
that the inhibition of squamous differentiation by retinoids is me-
diated by the nuclear retinoic acid receptor. The inhibition of cho-
lesterol sulfotransferase and transglutaminase type I, therefore, may 
occur at the transcriptional level. 
In summary, phorbol esters induce in NHEK cells a program of 
squamous differentiation. This process of differentiation consists of 
the commitment to terminal cell division (irreversible growth-ar-
rest) and expression of the squamous phenotype. Expression of this 
phenotype is accompanied by an accumulation of cholesterol sulfate 
and increased cholesterol sulfotransferase activity. Bryostatin 1 and 
2 and retinoic acid affect this differentiation process at different 
stages. 
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